⌕
Xeris Biopharma Holdings · XERS · Nasdaq
Tenet 48 · Mixed
Compare
$16.70+0.24%At closeTenet 48 · Mixed
$16.70+0.04 (+0.24%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Xeris Biopharma Holdings (XERS) Stock Checks

How XERS measures up against value, income, timing, and long-hold tenets. Every criterion shows the number as of the last close and the pass rule. Always free.

Sources Company filings and computed by Tenet Filings and TenetScreens as of How we compute thisNot investment advice

The tenets below and the 0-100 Tenet Score on this report are two separate computations: each tenet runs its own criteria and its own pass rule, while the score is a percentile composite reported as one of four verdict words (Strong, Solid, Mixed or Weak).

5 / 17 qualify todayas of close, Nov 13, 2026 · computed nightly from our fundamentals DB; point-in-time auditable.
QUALIFIES
5
meet every gate today
BORDERLINE
4
within one input of the gate
FAILS
5
miss at least one gate
UNKNOWN
3
insufficient data to judge
Buffett Qualitydurable moat
✕ Fails
FailsROE ≥ 15%−27.1% · ≥ 15.0%
PassesGross margin ≥ 40%87.4% · ≥ 40.0%
FailsNet margin ≥ 15%−1.8% · ≥ 15.0%
FailsDebt/equity ≤ 0.53.89 · ≤ 0.50
Unknown — no dataGrowing FCF (multi-yr)— · > 0
Decided by the pass rule for Buffett Quality.
The pass rule for Buffett Quality is what decides that verdict, and it is not restated here. 1 of 5 carry no data.Buffett Quality under The screens ›Today's Buffett Quality list ›
PassesReturn on assets positive0.1% · > 0
PassesOperating cash flow positive$28.6M · > 0
PassesReturn on assets improving−17.0% → 0.1%
PassesEarnings backed by cash (CFO > net income)$28.6M vs $554.0K
PassesLeverage falling (long-term debt / assets)67.2% → 57.4%
PassesCurrent ratio improving1.67 → 2.19
FailsNo share dilution (≤ +2%)+17.7%
PassesGross margin expanding81.9% → 85.4%
PassesAsset turnover improving0.63 → 0.76
Decided by the pass rule for Piotroski F-Score.
The badge above reads a pass with 1 of the checks below marked as failing. The pass rule for Piotroski F-Score is what decides that verdict, and it is not restated here.Piotroski F-Score under The screens ›Today's Piotroski F-Score list ›
PassesROIC ≥ 15%19.6% · ≥ 15.0%
PassesNet debt/EBITDA ≤ 3×0.9× · ≤ 3.0×
PassesAltman Z ≥ 3 (safe zone)4.27 · ≥ 3.00
Decided by the pass rule for Munger Compounders.
The pass rule for Munger Compounders is what decides that verdict, and it is not restated here.Munger Compounders under The screens ›Today's Munger Compounders list ›
PassesEBIT > 0$46.8M · > 0
FailsEarnings yield EBIT/EV ≥ 6%1.5% · ≥ 6.0%
PassesReturn on capital ≥ 25%29.3% · ≥ 25.0%
Decided by the pass rule for Magic Formula.
The pass rule for Magic Formula is what decides that verdict, and it is not published separately on the methodology page.About this screen ›Today's Magic Formula® list ›
PassesSize: market cap ≥ $2B$3.0B · ≥ $2.0B
PassesCurrent ratio ≥ 22.15 · ≥ 2.00
FailsPositive EPS 6yThe earnings per share on file for fiscal 2025 is zero while net income to common shareholders is positive, so that year is judged on net income.1y
FailsPays a dividend$0.00 · > 0
Unknown — no dataEPS growth ≥ 3%/yr— · ≥ 3.0%
Unknown — no dataP/E ≤ 15— · ≤ 15.00
Unknown — no dataP/E × P/B ≤ 22.5— · ≤ 22.50
Decided by the pass rule for Graham Defensive.
The pass rule for Graham Defensive is what decides that verdict, and it is not restated here. 3 of 7 carry no data.Graham Defensive under The screens ›Today's Graham Defensive list ›
Unknown — no dataPEG < 1 (hist. growth)— · < 1.00
Unknown — no dataEPS growth 10–30%— · 10.0%–30.0%
Verdict Unknown for this set.
Verdict Unknown for this set. None of the 2 checks below carry data.Lynch GARP under The screens ›Today's Lynch GARP list ›
FailsPays a dividend$0.00 · > 0
Unknown — no dataYield in a healthy band (not a yield trap)0.0% · 1.0%–8.0%
Unknown — no dataCovered by free cash flow— · ≥ 1.20
Unknown — no dataEarnings payout not stretched— · ≤ 75.0%
Unknown — no dataBalance sheet can sustain the payout0.9× · ≤ 4.0×
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 5 checks below carry data. The pass rule for Income & Dividend Safety is not published separately on the methodology page.
FailsPays a dividend$0.00 · > 0
Unknown — no dataAnnual dividend raised 10+ years running (Aristocrat ≥25, King ≥50)— · ≥ 10.00
Unknown — no dataNo dividend cut in the last 5 years—
Unknown — no data5-year dividend growth ≥ 5%/yr— · ≥ 5.0%
Unknown — no dataCovered by free cash flow— · ≥ 1.20
Unknown — no dataPayout not stretched— · ≤ 75.0%
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 6 checks below carry data.Dividend Growth under The screens ›Today's Dividend Growth list ›
FailsReturn on invested capital ≥ 15% in 4+ of the last 5 years0 of 5
PassesRevenue compounding ≥ 8%/yr over 5 years70.7% · ≥ 8.0%
FailsNot diluting: diluted share count flat-to-down (≤ +1%/yr)32.3% · ≤ 1.0%
Not scored: see the reason belowFree cash flow margin ≥ 12%Free-cash-flow margin isn't derivable yet from the statements we have on file.— · ≥ 12.0%
Not scored: see the reason belowEarnings backed by cash (operating cash flow ≥ net income)A loss year makes cash-vs-earnings unreadable: the ratio inverts over negative net income, so it is not scored (never counted against).— · ≥ 1.00
Reading: does not hold. Not a gate checkDisciplined buybacks: actively reducing the share count (bonus)reading, not a gate check32.3%
Decided by the pass rule for Quality Compounder.
The pass rule for Quality Compounder is what decides that verdict, and it is not restated here. 2 of 5 carry no data. Lines marked as readings are published beside the checks and are not gate checks.Quality Compounder under The screens ›Today's Quality Compounder list ›
FailsOff its 52-week high by 8–35% (a dip, not a collapse)1.3% · 8.0%–35.0%
PassesDip within its own normal pullback band0.16
PassesNot past where its dips have historically recovered from−5.24
PassesA dip in an uptrend (above a rising 200-day)7.83
PassesHigher-low structure still intactstructure intact · higher low
PassesClear of the earnings blackout (more than 5 days out)73.00 · > 5.00
Decided by the pass rule for Drawdown Context.
The pass rule for Drawdown Context is what decides that verdict, and it is not published separately on the methodology page.
PassesA bullish MACD cross within 10 sessions6.00 · ≤ 10.00
PassesReclaimed a rising 50-day EMA11.14
PassesPrinted a higher lowyes
FailsA volume thrust on the turn (≥ 1.2× normal)1.10 · ≥ 1.20
PassesReversal signals fired: 3 of 4 (MACD·MA·HL·Vol)3.00 · ≥ 3.00
Decided by the pass rule for Reversal Evidence.
The badge above reads a pass with 1 of the checks below marked as failing. The pass rule for Reversal Evidence is what decides that verdict, and it is not published separately on the methodology page.
Unknown — no dataIn the cheap half of its own 5-year valuation range—
FailsEarnings estimates not being cut−1.12
PassesReturns on capital not deteriorating0.11
Decided by the pass rule for Not-a-Value-Trap Gate.
The pass rule for Not-a-Value-Trap Gate is what decides that verdict, and it is not published separately on the methodology page. 1 of 3 carry no data.
PassesOperating profit is positive$46.8M · > 0
PassesReturn on invested capital ≥ 10%19.6% · ≥ 10.0%
PassesA solvent balance sheet (Altman Z ≥ 1.8, net debt/EBITDA ≤ 4)4.3×
PassesQuality score ≥ 5065.10 · ≥ 50.00
PassesRevenue growing over 5 years70.7% · > 0
Decided by the pass rule for Quality Floor.
The pass rule for Quality Floor is what decides that verdict, and it is not published separately on the methodology page.
A research signal from published criteria, not a recommendation.
FailsDrawdown context1.3% off its 52-week high
PassesReversal evidence3 of 4 signals fired
FailsTrap gate1 of 3 held · 1 no data
PassesQuality floor5 of 5 held
Invalidation level (structure break): below this the dip's structure has broken$7.36
Decided by the pass rule for Qualified Dip.
The pass rule for Qualified Dip is what decides that verdict, and it is not restated here.Qualified Dip under The screens ›Today's Qualified Dip list ›
PassesTrading above its 50-day average10.40
PassesTrading above its 200-day average7.83
Passes50-day average above the 200-day (uptrend stack)10.40
Passes50-day average sloping up0.18 · > 0
Decided by the pass rule for Trend Alignment.
The pass rule for Trend Alignment is what decides that verdict, and it is not published separately on the methodology page.
Passes3-month return in the top half of the universe1.00 · ≥ 0.50
Passes12-minus-1 momentum in the top half of the universe0.75 · ≥ 0.50
PassesRelative strength vs the S&P 500 improving0.01 · > 0
FailsEarnings estimates being revised up−1.12
Decided by the pass rule for Relative Strength.
The pass rule for Relative Strength is what decides that verdict, and it is not published separately on the methodology page.
PassesMACD above its signal line1.74
PassesBack above the 50-day on a fresh cross (≤10 sessions)6.00
FailsHigher high and higher low (stair-stepping up)no higher high · higher low
FailsA volume thrust on the move (≥ 1.2× normal)1.10 · ≥ 1.20
Decided by the pass rule for Momentum Trigger.
The pass rule for Momentum Trigger is what decides that verdict, and it is not published separately on the methodology page.
Average daily swing: elevated0.05
Volatility band width: expanded (wide range)1.00
Distance from its 52-week high: at / near its highs0.01
Every verdict is auditableEach criterion shows the number as of the last close and the pass rule side by side: a receipt, not a rating. Several of these screens publish their rule in full under The screens; each row links to its own section where there is one.
Unknown ≠ failAn “— Unknown” verdict means the inputs were insufficient: context, not a signal, and never counted as a fail.

How many investing rule sets does Xeris Biopharma Holdings pass?

Xeris Biopharma Holdings qualifies on 5 of 17 rule sets as of 2026-11-13, with 4 borderline and 5 failing.

Does Xeris Biopharma Holdings meet the Graham Defensive criteria?

Xeris Biopharma Holdings fails the Graham Defensive rule set as of 2026-11-13.

Does Xeris Biopharma Holdings meet the Buffett Quality criteria?

Xeris Biopharma Holdings fails the Buffett Quality rule set as of 2026-11-13.

Computed from our fundamentals DB; historical-CAGR PEG basis for Lynch. Research, not investment advice. Tenet's rulesets are independently developed from publicly available sources, and Tenet is not affiliated with, sponsored by, endorsed by or otherwise associated with any referenced investor or trademark owner. Full notice. MAGIC FORMULA is a trademark of MagicFormulaInvesting.com LLC.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.